Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial.

Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, Chen CC, Hsu SJ, Hsu YC, Tseng CH, Tseng PH, Chang L, Chang WH, Wang HP, Shun CT, Wu JY, Lee YC, Lin JT, Wu MS; Taiwan Helicobacter Consortium.

J Antimicrob Chemother. 2013 Feb;68(2):450-6. doi: 10.1093/jac/dks407. Epub 2012 Oct 25.

PMID:
23099849
2.

Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.

Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT.

J Antimicrob Chemother. 2011 Aug;66(8):1847-52. doi: 10.1093/jac/dkr217. Epub 2011 May 31.

PMID:
21632579
3.

Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.

Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H.

Clin Gastroenterol Hepatol. 2013 Jul;11(7):802-7.e1. doi: 10.1016/j.cgh.2013.01.008. Epub 2013 Jan 29.

PMID:
23376004
4.

Multiple Genetic Analysis System-Based Antibiotic Susceptibility Testing in Helicobacter pylori and High Eradication Rate With Phenotypic Resistance-Guided Quadruple Therapy.

Dong F, Ji D, Huang R, Zhang F, Huang Y, Xiang P, Kong M, Nan L, Zeng X, Wu Y, Bao Z.

Medicine (Baltimore). 2015 Nov;94(47):e2056. doi: 10.1097/MD.0000000000002056.

5.

Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.

Wu IT, Chuah SK, Lee CH, Liang CM, Lu LS, Kuo YH, Yen YH, Hu ML, Chou YP, Yang SC, Kuo CM, Kuo CH, Chien CC, Chiang YS, Chiou SS, Hu TH, Tai WC.

World J Gastroenterol. 2015 Oct 7;21(37):10669-74. doi: 10.3748/wjg.v21.i37.10669.

6.

Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance.

Tong YF, Lv J, Ying LY, Xu F, Qin B, Chen MT, Meng F, Tu MY, Yang NM, Li YM, Zhang JZ.

World J Gastroenterol. 2015 Dec 14;21(46):13073-9. doi: 10.3748/wjg.v21.i46.13073.

7.

Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy.

Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, Xiao S, Graham DY, Lu H.

Helicobacter. 2013 Oct;18(5):373-7. doi: 10.1111/hel.12052. Epub 2013 Apr 15.

8.

Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial.

Liou JM, Bair MJ, Chen CC, Lee YC, Chen MJ, Chen CC, Tseng CH, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Chang WH, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hung HW, Lin JT, Chang CY, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

Am J Gastroenterol. 2016 Mar;111(3):381-7. doi: 10.1038/ajg.2015.439. Epub 2016 Feb 2.

PMID:
26832653
9.

The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication.

Tai WC, Lee CH, Chiou SS, Kuo CM, Kuo CH, Liang CM, Lu LS, Chiu CH, Wu KL, Chiu YC, Hu TH, Chuah SK.

PLoS One. 2014 Aug 20;9(8):e105822. doi: 10.1371/journal.pone.0105822. eCollection 2014.

10.

Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.

Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Masaoka T, Kanai T.

Helicobacter. 2016 Aug;21(4):286-94. doi: 10.1111/hel.12286. Epub 2015 Nov 27.

PMID:
26612407
11.

Primary resistance of Helicobacter pylori is still low in Southern Austria.

Zollner-Schwetz I, Leitner E, Plieschnegger W, Semlitsch G, Stepan V, Reiter L, Reicht G, Mörth E, Pavek J, Parsché P, Betterklieber C, Atzmüller D, Krause R, Högenauer C.

Int J Med Microbiol. 2016 Jun;306(4):206-11. doi: 10.1016/j.ijmm.2016.04.003. Epub 2016 Apr 23.

PMID:
27134190
12.

Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods.

Ducournau A, Bénéjat L, Sifré E, Bessède E, Lehours P, Mégraud F.

Clin Microbiol Infect. 2016 Aug;22(8):715-8. doi: 10.1016/j.cmi.2016.06.003. Epub 2016 Jun 23.

13.

Helicobacter pylori antibiotic susceptibility patterns in Bangladesh: Emerging levofloxacin resistance.

Aftab H, Miftahussurur M, Subsomwong P, Ahmed F, Khan AK, Yamaoka Y.

J Infect Dev Ctries. 2016 Mar 31;10(3):245-53. doi: 10.3855/jidc.7713.

14.

Sequential Therapy for Helicobacter pylori Infection in Treatment-naïve Children.

Schwarzer A, Bontems P, Urruzuno P, Kalach N, Iwanczak B, Roma-Giannikou E, Sykora J, Kindermann A, Casswall T, Cadranel S, Koletzko S.

Helicobacter. 2016 Apr;21(2):106-13. doi: 10.1111/hel.12240. Epub 2015 Jun 30.

PMID:
26123402
15.

Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre.

O'Connor A, Taneike I, Nami A, Fitzgerald N, Ryan B, Breslin N, O'Connor H, McNamara D, Murphy P, O'Morain C.

Ir J Med Sci. 2013 Dec;182(4):693-5. doi: 10.1007/s11845-013-0957-3. Epub 2013 Apr 27.

PMID:
23625165
16.

Outcome of second- and third-line Helicobacter pylori eradication therapies based on antimicrobial susceptibility testing.

Draeger S, Wüppenhorst N, Kist M, Glocker EO.

J Antimicrob Chemother. 2015 Nov;70(11):3141-5. doi: 10.1093/jac/dkv223. Epub 2015 Aug 5.

PMID:
26245638
17.

The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam.

Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y.

J Clin Gastroenterol. 2013 Mar;47(3):233-8. doi: 10.1097/MCG.0b013e3182676e2b.

18.

[Helicobacter pylori resistance: who needs what treatment?].

Courillon-Mallet A.

Presse Med. 2006 Apr;35(4 Pt 2):657-62. Review. French.

PMID:
16614611
19.

Long-term colonization with single and multiple strains of Helicobacter pylori assessed by DNA fingerprinting.

Taylor NS, Fox JG, Akopyants NS, Berg DE, Thompson N, Shames B, Yan L, Fontham E, Janney F, Hunter FM, et al.

J Clin Microbiol. 1995 Apr;33(4):918-23.

20.

Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes.

Yang YJ, Wu CT, Ou HY, Lin CH, Cheng HC, Chang WL, Chen WY, Yang HB, Lu CC, Sheu BS.

Ann Med. 2017 Sep;49(6):479-486. doi: 10.1080/07853890.2017.1294761. Epub 2017 Mar 7.

PMID:
28266875

Supplemental Content

Support Center